iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)

Last updated: August 9, 2022
Sponsor: Changhai Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Digestive System Neoplasms

Cancer

Treatment

N/A

Clinical Study ID

NCT05495685
CHEC2022-030
  • Ages 40-75
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. The sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.

Eligibility Criteria

Inclusion

Inclusion Criteria for Cancer Arm Participants:

  • Able to provide a written informed consent.

  • Able to provide sufficient and qualified blood samples for study tests.

  • No prior or undergoing cancer treatment (local or systematic) with either of the following:

  • A. Pathologically confirmed cancer diagnosis within 42 days prior to the study blood draw.

  • B. High suspicious for cancer diagnosis by radiological or other routine clinical assessments, with confirmed cancer diagnosis through biopsy or surgical resection within 42 days after study blood draw.

Exclusion Criteria for Cancer Arm Participants:

  • Insufficient qualified blood sample for study test.

  • During pregnancy or lactation.

  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.

  • Recipient of blood transfusion within 30 days prior to study blood draw.

  • With other known malignant tumors or multiple primary tumors.

Inclusion Criteria for Benign Disease Arm Participants:

  • Able to provide a written informed consent.

  • Able to provide sufficient and qualified blood samples for study tests.

  • Have either of the following:

  • A. Pathological confirmed diagnosis of benign diseases within 90 days prior to the study blood draw, with no prior treatment such as surgical resection.

  • B. High suspicious for benign diseases diagnosis by radiological or other routine clinical assessments, with confirmed benign diseases diagnosis within 42 days after study blood draw.

Exclusion Criteria for Benign Disease Arm Participants:

  • Insufficient qualified blood sample for study test.

  • During pregnancy or lactation.

  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.

  • Recipient of blood transfusion within 30 days prior to study blood draw.

  • Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer

Study Design

Total Participants: 450
Study Start date:
March 24, 2022
Estimated Completion Date:
June 30, 2024

Connect with a study center

  • Shanghai Changhai Hospital

    Shanghai, Shanghai 200433
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.